Foghorn Therapeutics Inc. (FHTX) 10-Year Financial Performance & Capital Metrics

FHTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $23M -33.8%
EBITDA -$100M +4.7%
Net Income -$87M +12.0%
EPS (Diluted) -1.58 +32.5%
Gross Margin 100%
EBITDA Margin -440.51% -44.0%
Operating Margin -454.31% -43.8%
Net Margin -383.24% -33.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 30.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y157.81%

TTM-3.91%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM40.63%

ROCE

10Y Avg-67.04%

5Y Avg-39.24%

3Y Avg-37.38%

Latest-46.2%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	430K	1.32M	19.23M	34.16M	22.6M
Revenue Growth %	-	-	-	2.07%	13.58%	0.78%	-0.34%
Cost of Goods Sold+	379K	1.79M	57.72M	0	0	0	0
COGS % of Revenue	-	-	134.22%	-	-	-	-
Gross Profit+	-379K	-1.79M	-57.28M	1.32M	19.23M	34.16M	22.6M
Gross Margin %	-	-	-133.22%	1%	1%	1%	1%
Gross Profit Growth %	-	-3.73%	-30.95%	1.02%	13.58%	0.78%	-0.34%
Operating Expenses+	26.05M	49.29M	11.25M	102.05M	136.37M	142.06M	125.28M
OpEx % of Revenue	-	-	26.15%	77.37%	7.09%	4.16%	5.54%
Selling, General & Admin	4.82M	4.93M	11.25M	21.73M	30.75M	32.37M	28.36M
SG&A % of Revenue	-	-	26.15%	16.47%	1.6%	0.95%	1.25%
Research & Development	21.23M	44.36M	57.72M	80.33M	105.62M	109.69M	94.53M
R&D % of Revenue	-	-	134.22%	60.9%	5.49%	3.21%	4.18%
Other Operating Expenses	0	0	-57.72M	0	0	0	2.4M
Operating Income+	-26.05M	-51.08M	-68.53M	-100.73M	-117.14M	-107.91M	-102.68M
Operating Margin %	-	-	-159.37%	-76.37%	-6.09%	-3.16%	-4.54%
Operating Income Growth %	-	-0.96%	-0.34%	-0.47%	-0.16%	0.08%	0.05%
EBITDA+	-25.67M	-49.29M	-67.2M	-97.51M	-113.82M	-104.45M	-99.56M
EBITDA Margin %	-	-	-156.29%	-73.92%	-5.92%	-3.06%	-4.41%
EBITDA Growth %	-	-0.92%	-0.36%	-0.45%	-0.17%	0.08%	0.05%
D&A (Non-Cash Add-back)	379K	1.79M	1.33M	3.23M	3.32M	3.45M	3.12M
EBIT	-25.97M	-50.59M	-68.53M	-99.41M	-117.14M	-107.91M	-100.28M
Net Interest Income+	-258K	-45K	22K	-1.85M	5.67M	10.88M	11.9M
Interest Income	113K	495K	1M	59K	5.67M	10.88M	11.9M
Interest Expense	371K	540K	979K	1.91M	0	0	0
Other Income/Expense	-288K	-44K	-269K	-586K	8.26M	13.71M	16.06M
Pretax Income+	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-94.2M	-86.62M
Pretax Margin %	-	-	-160%	-76.82%	-5.66%	-2.76%	-3.83%
Income Tax+	83K	0	0	0	0	4.23M	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1.04%	1%
Net Income+	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-98.43M	-86.62M
Net Margin %	-	-	-160%	-76.82%	-5.66%	-2.88%	-3.83%
Net Income Growth %	-	-0.94%	-0.35%	-0.47%	-0.07%	0.1%	0.12%
Net Income (Continuing)	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-98.43M	-86.62M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-1.34	-1.40	-1.90	-2.78	-2.62	-2.34	-1.58
EPS Growth %	-	-0.04%	-0.36%	-0.46%	0.06%	0.11%	0.32%
EPS (Basic)	-1.34	-1.40	-1.90	-2.78	-2.62	-2.34	-1.58
Diluted Shares Outstanding	19.63M	36.82M	36.79M	37.17M	41.59M	41.97M	54.9M
Basic Shares Outstanding	19.63M	36.82M	36.79M	37.17M	41.59M	41.97M	54.9M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	40.4M	16.89M	190.69M	459.56M	351.4M	240.18M	249.6M
Cash & Short-Term Investments	40.02M	14.98M	185.77M	154.29M	345.8M	234.06M	243.75M
Cash Only	40.02M	14.98M	92.8M	101.14M	52.21M	80.34M	55.45M
Short-Term Investments	0	0	92.97M	53.15M	293.58M	153.72M	188.29M
Accounts Receivable	0	0	0	300M	0	0	0
Days Sales Outstanding	-	-	-	83.02K	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	541K	0	0	5.6M	6.12M	5.85M
Total Non-Current Assets+	2.66M	5.46M	64.91M	60.21M	53.48M	45.73M	34.38M
Property, Plant & Equipment	2.09M	3.71M	62.33M	56.08M	49.4M	42.91M	32.6M
Fixed Asset Turnover	-	-	0.01x	0.02x	0.39x	0.80x	0.69x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	566K	0	0	0	0	0	0
Other Non-Current Assets	0	1.74M	2.58M	4.13M	4.09M	2.82M	1.78M
Total Assets+	43.06M	22.34M	255.59M	519.77M	404.88M	285.92M	283.98M
Asset Turnover	-	-	0.00x	0.00x	0.05x	0.12x	0.08x
Asset Growth %	-	-0.48%	10.44%	1.03%	-0.22%	-0.29%	-0.01%
Total Current Liabilities+	3.46M	12.65M	18.85M	48.69M	55.2M	58.44M	66.99M
Accounts Payable	2.01M	3.44M	3.68M	3.82M	5.41M	6.26M	3.79M
Days Payables Outstanding	1.94K	700.08	23.27	-	-	-	-
Short-Term Debt	0	4.15M	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	1.92M	3.65M	5.99M	5.06M	4.38M	4.74M
Current Ratio	11.68x	1.33x	10.12x	9.44x	6.37x	4.11x	3.73x
Quick Ratio	11.68x	1.33x	10.12x	9.44x	6.37x	4.11x	3.73x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	78.87M	97.71M	90.56M	374.21M	349.57M	304.67M	262.52M
Long-Term Debt	7.03M	10.96M	19.65M	0	0	0	0
Capital Lease Obligations	0	157K	58.36M	51.34M	45.54M	36.55M	28.06M
Deferred Tax Liabilities	-547K	0	0	0	0	0	0
Other Non-Current Liabilities	71.84M	86.59M	0	143K	29K	0	0
Total Liabilities	82.33M	110.36M	109.41M	422.9M	404.77M	363.11M	329.51M
Total Debt+	7.03M	16.63M	82M	58.33M	51.51M	45.07M	37.13M
Net Debt	-32.99M	1.65M	-10.8M	-42.8M	-707K	-35.26M	-18.32M
Debt / Equity	-	-	0.56x	0.60x	459.88x	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-70.21x	-94.60x	-70.00x	-52.85x	-	-	-
Total Equity+	-39.27M	-88.02M	146.19M	96.87M	112K	-77.19M	-45.53M
Equity Growth %	-	-1.24%	2.66%	-0.34%	-1%	-690.2%	0.41%
Book Value per Share	-2.00	-2.39	3.97	2.61	0.00	-1.84	-0.83
Total Shareholders' Equity	-39.27M	-88.02M	146.19M	96.87M	112K	-77.19M	-45.53M
Common Stock	1K	0	4K	4K	4K	4K	6K
Retained Earnings	-43.01M	-94.14M	-162.94M	-264.26M	-373.14M	-471.56M	-558.18M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-616K	0	-7K	-10K	-3.99M	-826K	135K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.65M	-46.34M	-31.29M	-50.25M	193.61M	-118.11M	-100.41M
Operating CF Margin %	-	-	-72.76%	-38.1%	10.07%	-3.46%	-4.44%
Operating CF Growth %	-	-1.05%	0.32%	-0.61%	4.85%	-1.61%	0.15%
Net Income	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-98.43M	-86.62M
Depreciation & Amortization	379K	693K	1.33M	3.23M	7.9M	3.45M	3.12M
Stock-Based Compensation	732K	1.69M	2.96M	8.38M	0	16.19M	11.89M
Deferred Taxes	30K	0	84K	1.41M	0	0	0
Other Non-Cash Items	124K	1.21M	4.44M	4.61M	13.05M	2.56M	3.47M
Working Capital Changes	2.42M	1.2M	28.7M	33.44M	281.55M	-41.88M	-32.27M
Change in Receivables	0	0	0	-300M	300M	0	0
Change in Inventory	0	0	0	-3.17M	0	0	0
Change in Payables	1.28M	1.21M	474K	135K	1.61M	846K	-2.48M
Cash from Investing+	-1.54M	-964K	-108.91M	36.17M	-244.32M	144.45M	-29.9M
Capital Expenditures	-1.54M	-968K	-16.18M	-3.31M	-1.21M	-1.22M	-906K
CapEx % of Revenue	-	-	37.63%	2.51%	0.06%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	4K	250K	39.49M	0	0	0
Cash from Financing+	51.77M	23.97M	217.47M	22.42M	1.76M	1.78M	105.43M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	190K	691K	1.22M	1.42M	0	1.78M	2.03M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-24.19M	-47.3M	-47.47M	-53.56M	192.4M	-119.33M	-101.31M
FCF Margin %	-	-	-110.39%	-40.61%	10.01%	-3.49%	-4.48%
FCF Growth %	-	-0.96%	-0%	-0.13%	4.59%	-1.62%	0.15%
FCF per Share	-1.23	-1.28	-1.29	-1.44	4.63	-2.84	-1.85
FCF Conversion (FCF/Net Income)	0.86x	0.91x	0.45x	0.50x	-1.78x	1.20x	1.16x
Interest Paid	0	420K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	3.55M	860K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-236.54%	-83.37%	-224.54%	-	-
Return on Invested Capital (ROIC)	-	-	-209.7%	-79.76%	-328.59%	-	-
Gross Margin	-	-	-13322.09%	100%	100%	100%	100%
Net Margin	-	-	-16000%	-7681.58%	-566.27%	-288.17%	-383.24%
Debt / Equity	-	-	0.56x	0.60x	459.88x	-	-
Interest Coverage	-70.21x	-94.60x	-70.00x	-52.85x	-	-	-
FCF Conversion	0.86x	0.91x	0.45x	0.50x	-1.78x	1.20x	1.16x
Revenue Growth	-	-	-	206.74%	1357.77%	77.63%	-33.83%

Frequently Asked Questions

Growth & Financials

Foghorn Therapeutics Inc. (FHTX) reported $24.5M in revenue for fiscal year 2024.

Foghorn Therapeutics Inc. (FHTX) saw revenue decline by 33.8% over the past year.

Foghorn Therapeutics Inc. (FHTX) reported a net loss of $72.1M for fiscal year 2024.

Dividend & Returns

Foghorn Therapeutics Inc. (FHTX) had negative free cash flow of $88.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Foghorn Therapeutics Inc. (FHTX) 10-Year Financial Performance & Capital Metrics

FHTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $23M -33.8%
EBITDA -$100M +4.7%
Net Income -$87M +12.0%
EPS (Diluted) -1.58 +32.5%
Gross Margin 100%
EBITDA Margin -440.51% -44.0%
Operating Margin -454.31% -43.8%
Net Margin -383.24% -33.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 30.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y157.81%

TTM-3.91%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM40.63%

ROCE

10Y Avg-67.04%

5Y Avg-39.24%

3Y Avg-37.38%

Latest-46.2%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	430K	1.32M	19.23M	34.16M	22.6M
Revenue Growth %	-	-	-	2.07%	13.58%	0.78%	-0.34%
Cost of Goods Sold+	379K	1.79M	57.72M	0	0	0	0
COGS % of Revenue	-	-	134.22%	-	-	-	-
Gross Profit+	-379K	-1.79M	-57.28M	1.32M	19.23M	34.16M	22.6M
Gross Margin %	-	-	-133.22%	1%	1%	1%	1%
Gross Profit Growth %	-	-3.73%	-30.95%	1.02%	13.58%	0.78%	-0.34%
Operating Expenses+	26.05M	49.29M	11.25M	102.05M	136.37M	142.06M	125.28M
OpEx % of Revenue	-	-	26.15%	77.37%	7.09%	4.16%	5.54%
Selling, General & Admin	4.82M	4.93M	11.25M	21.73M	30.75M	32.37M	28.36M
SG&A % of Revenue	-	-	26.15%	16.47%	1.6%	0.95%	1.25%
Research & Development	21.23M	44.36M	57.72M	80.33M	105.62M	109.69M	94.53M
R&D % of Revenue	-	-	134.22%	60.9%	5.49%	3.21%	4.18%
Other Operating Expenses	0	0	-57.72M	0	0	0	2.4M
Operating Income+	-26.05M	-51.08M	-68.53M	-100.73M	-117.14M	-107.91M	-102.68M
Operating Margin %	-	-	-159.37%	-76.37%	-6.09%	-3.16%	-4.54%
Operating Income Growth %	-	-0.96%	-0.34%	-0.47%	-0.16%	0.08%	0.05%
EBITDA+	-25.67M	-49.29M	-67.2M	-97.51M	-113.82M	-104.45M	-99.56M
EBITDA Margin %	-	-	-156.29%	-73.92%	-5.92%	-3.06%	-4.41%
EBITDA Growth %	-	-0.92%	-0.36%	-0.45%	-0.17%	0.08%	0.05%
D&A (Non-Cash Add-back)	379K	1.79M	1.33M	3.23M	3.32M	3.45M	3.12M
EBIT	-25.97M	-50.59M	-68.53M	-99.41M	-117.14M	-107.91M	-100.28M
Net Interest Income+	-258K	-45K	22K	-1.85M	5.67M	10.88M	11.9M
Interest Income	113K	495K	1M	59K	5.67M	10.88M	11.9M
Interest Expense	371K	540K	979K	1.91M	0	0	0
Other Income/Expense	-288K	-44K	-269K	-586K	8.26M	13.71M	16.06M
Pretax Income+	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-94.2M	-86.62M
Pretax Margin %	-	-	-160%	-76.82%	-5.66%	-2.76%	-3.83%
Income Tax+	83K	0	0	0	0	4.23M	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1.04%	1%
Net Income+	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-98.43M	-86.62M
Net Margin %	-	-	-160%	-76.82%	-5.66%	-2.88%	-3.83%
Net Income Growth %	-	-0.94%	-0.35%	-0.47%	-0.07%	0.1%	0.12%
Net Income (Continuing)	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-98.43M	-86.62M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-1.34	-1.40	-1.90	-2.78	-2.62	-2.34	-1.58
EPS Growth %	-	-0.04%	-0.36%	-0.46%	0.06%	0.11%	0.32%
EPS (Basic)	-1.34	-1.40	-1.90	-2.78	-2.62	-2.34	-1.58
Diluted Shares Outstanding	19.63M	36.82M	36.79M	37.17M	41.59M	41.97M	54.9M
Basic Shares Outstanding	19.63M	36.82M	36.79M	37.17M	41.59M	41.97M	54.9M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	40.4M	16.89M	190.69M	459.56M	351.4M	240.18M	249.6M
Cash & Short-Term Investments	40.02M	14.98M	185.77M	154.29M	345.8M	234.06M	243.75M
Cash Only	40.02M	14.98M	92.8M	101.14M	52.21M	80.34M	55.45M
Short-Term Investments	0	0	92.97M	53.15M	293.58M	153.72M	188.29M
Accounts Receivable	0	0	0	300M	0	0	0
Days Sales Outstanding	-	-	-	83.02K	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	541K	0	0	5.6M	6.12M	5.85M
Total Non-Current Assets+	2.66M	5.46M	64.91M	60.21M	53.48M	45.73M	34.38M
Property, Plant & Equipment	2.09M	3.71M	62.33M	56.08M	49.4M	42.91M	32.6M
Fixed Asset Turnover	-	-	0.01x	0.02x	0.39x	0.80x	0.69x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	566K	0	0	0	0	0	0
Other Non-Current Assets	0	1.74M	2.58M	4.13M	4.09M	2.82M	1.78M
Total Assets+	43.06M	22.34M	255.59M	519.77M	404.88M	285.92M	283.98M
Asset Turnover	-	-	0.00x	0.00x	0.05x	0.12x	0.08x
Asset Growth %	-	-0.48%	10.44%	1.03%	-0.22%	-0.29%	-0.01%
Total Current Liabilities+	3.46M	12.65M	18.85M	48.69M	55.2M	58.44M	66.99M
Accounts Payable	2.01M	3.44M	3.68M	3.82M	5.41M	6.26M	3.79M
Days Payables Outstanding	1.94K	700.08	23.27	-	-	-	-
Short-Term Debt	0	4.15M	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	1.92M	3.65M	5.99M	5.06M	4.38M	4.74M
Current Ratio	11.68x	1.33x	10.12x	9.44x	6.37x	4.11x	3.73x
Quick Ratio	11.68x	1.33x	10.12x	9.44x	6.37x	4.11x	3.73x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	78.87M	97.71M	90.56M	374.21M	349.57M	304.67M	262.52M
Long-Term Debt	7.03M	10.96M	19.65M	0	0	0	0
Capital Lease Obligations	0	157K	58.36M	51.34M	45.54M	36.55M	28.06M
Deferred Tax Liabilities	-547K	0	0	0	0	0	0
Other Non-Current Liabilities	71.84M	86.59M	0	143K	29K	0	0
Total Liabilities	82.33M	110.36M	109.41M	422.9M	404.77M	363.11M	329.51M
Total Debt+	7.03M	16.63M	82M	58.33M	51.51M	45.07M	37.13M
Net Debt	-32.99M	1.65M	-10.8M	-42.8M	-707K	-35.26M	-18.32M
Debt / Equity	-	-	0.56x	0.60x	459.88x	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-70.21x	-94.60x	-70.00x	-52.85x	-	-	-
Total Equity+	-39.27M	-88.02M	146.19M	96.87M	112K	-77.19M	-45.53M
Equity Growth %	-	-1.24%	2.66%	-0.34%	-1%	-690.2%	0.41%
Book Value per Share	-2.00	-2.39	3.97	2.61	0.00	-1.84	-0.83
Total Shareholders' Equity	-39.27M	-88.02M	146.19M	96.87M	112K	-77.19M	-45.53M
Common Stock	1K	0	4K	4K	4K	4K	6K
Retained Earnings	-43.01M	-94.14M	-162.94M	-264.26M	-373.14M	-471.56M	-558.18M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-616K	0	-7K	-10K	-3.99M	-826K	135K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.65M	-46.34M	-31.29M	-50.25M	193.61M	-118.11M	-100.41M
Operating CF Margin %	-	-	-72.76%	-38.1%	10.07%	-3.46%	-4.44%
Operating CF Growth %	-	-1.05%	0.32%	-0.61%	4.85%	-1.61%	0.15%
Net Income	-26.34M	-51.13M	-68.8M	-101.32M	-108.88M	-98.43M	-86.62M
Depreciation & Amortization	379K	693K	1.33M	3.23M	7.9M	3.45M	3.12M
Stock-Based Compensation	732K	1.69M	2.96M	8.38M	0	16.19M	11.89M
Deferred Taxes	30K	0	84K	1.41M	0	0	0
Other Non-Cash Items	124K	1.21M	4.44M	4.61M	13.05M	2.56M	3.47M
Working Capital Changes	2.42M	1.2M	28.7M	33.44M	281.55M	-41.88M	-32.27M
Change in Receivables	0	0	0	-300M	300M	0	0
Change in Inventory	0	0	0	-3.17M	0	0	0
Change in Payables	1.28M	1.21M	474K	135K	1.61M	846K	-2.48M
Cash from Investing+	-1.54M	-964K	-108.91M	36.17M	-244.32M	144.45M	-29.9M
Capital Expenditures	-1.54M	-968K	-16.18M	-3.31M	-1.21M	-1.22M	-906K
CapEx % of Revenue	-	-	37.63%	2.51%	0.06%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	4K	250K	39.49M	0	0	0
Cash from Financing+	51.77M	23.97M	217.47M	22.42M	1.76M	1.78M	105.43M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	190K	691K	1.22M	1.42M	0	1.78M	2.03M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-24.19M	-47.3M	-47.47M	-53.56M	192.4M	-119.33M	-101.31M
FCF Margin %	-	-	-110.39%	-40.61%	10.01%	-3.49%	-4.48%
FCF Growth %	-	-0.96%	-0%	-0.13%	4.59%	-1.62%	0.15%
FCF per Share	-1.23	-1.28	-1.29	-1.44	4.63	-2.84	-1.85
FCF Conversion (FCF/Net Income)	0.86x	0.91x	0.45x	0.50x	-1.78x	1.20x	1.16x
Interest Paid	0	420K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	3.55M	860K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-236.54%	-83.37%	-224.54%	-	-
Return on Invested Capital (ROIC)	-	-	-209.7%	-79.76%	-328.59%	-	-
Gross Margin	-	-	-13322.09%	100%	100%	100%	100%
Net Margin	-	-	-16000%	-7681.58%	-566.27%	-288.17%	-383.24%
Debt / Equity	-	-	0.56x	0.60x	459.88x	-	-
Interest Coverage	-70.21x	-94.60x	-70.00x	-52.85x	-	-	-
FCF Conversion	0.86x	0.91x	0.45x	0.50x	-1.78x	1.20x	1.16x
Revenue Growth	-	-	-	206.74%	1357.77%	77.63%	-33.83%

Frequently Asked Questions

Growth & Financials

Foghorn Therapeutics Inc. (FHTX) reported $24.5M in revenue for fiscal year 2024.

Foghorn Therapeutics Inc. (FHTX) saw revenue decline by 33.8% over the past year.

Foghorn Therapeutics Inc. (FHTX) reported a net loss of $72.1M for fiscal year 2024.

Dividend & Returns

Foghorn Therapeutics Inc. (FHTX) had negative free cash flow of $88.9M in fiscal year 2024, likely due to heavy capital investments.